• Lp(a)

  • Sources:

    There is limited direct discussion on Lp(a), which stands for Lipoprotein(a), in the Huberman Lab podcast. However, , in a conversation with , briefly touches on particles closely related to Lp(a). Dr. Attia explains that Apolipoprotein B (ApoB) is the causative agent in atherosclerosis and how it's important to keep levels of ApoB low to prevent heart disease. He mentions that LDL includes the LP Little A, although he notes that the concentration of LP Little A is relatively small and does not generally show up as much in the ApoB measurement 1. Moreover, Dr. Attia describes LP Little A as a special type of LDL, which in about 10-20% of the population can be particularly harmful 2.

    ApoB is a protein found in lipoproteins that are responsible for transporting cholesterol and triglycerides through the bloodstream. Lp(a) is a type of LDL cholesterol that is bound to a specific type of ApoB that includes an additional protein called apolipoprotein(a). Elevated levels of Lp(a) are considered a risk factor for cardiovascular disease. While Dr. Attia does not provide in-depth knowledge specifically about Lp(a), his discussion underlines its relation to ApoB and its role in cardiovascular risk 1 2.

  • RELATED QUESTIONS
  • I want to learn more about Lipoprotein(a) (Lp(a)).

  • Sources:

    Lipoprotein(a), or Lp(a), is a special type of LDL (low-density lipoprotein) that in 10-20% of the population can be a really harmful actor, as mentioned by . Lp(a) carries cholesterol in the blood and is associated with an increased risk of developing atherosclerosis. Attia explains that Lp(a) includes another apolipoprotein on it called apolipoprotein(a) 1.

    While Lp(a) has a role in the development of cardiovascular diseases, it's also noted that the density of Lp(a) is relatively small and may not show up as much in the measurement of ApoB, which is the protein that permits lipoproteins to move through our circulation. It’s important to note that ApoB is the causative agent of atherosclerosis and is something that needs to be kept at a low level to prevent such disease 2.

    Overall, Lp(a) is a specific focus within the larger context of lipid management and cardiovascular risk. For more comprehensive information on lipid management and atherosclerosis prevention, it would be beneficial to delve into full discussions on these topics from and other experts featured in the .

  • RELATED QUESTIONS
  • List clips similar to "Atherosclerosis Prevention"

  • Sources:

    Here are some clips similar to "Atherosclerosis Prevention":

    1. "Atherosclerosis Prevention" - Dr. Peter Attia discusses the importance of ApoB, the causative agent of atherosclerosis, and its management 1.

    2. "Preventing Arterial Atherosclerosis" - The top ways to prevent arterial atherosclerosis, emphasizing blood pressure control, smoking cessation, and reducing ApoB lipoproteins exposure 2.

    3. "Blood Testing Frequency" - Reasons to undergo early screening for LP Little A, a significant genetic driver of atherosclerosis 3.

    4. "Longevity's Greatest Struggle" - Peter Attia stresses the crucial role of emotional health in longevity and his personal approach to managing the risk of atherosclerosis 4.

    5. "Potent Cholesterol Drugs" - Peter Attia discusses potent cholesterol medications like PCSK nine inhibitors and their role in lowering cholesterol levels to prevent heart disease 5.

    6. "Heart Disease Prevention" - The need for proactive measures in ApoB level management and cholesterol intake custom-tailored to individual health objectives 6.

    7. "Genetics and Atherosclerosis" - The importance of intervention in high ApoB levels despite the absence of symptoms, with a focus on the asymptomatic nature of atherosclerosis 7.

    8. "Cancer Prevention" - A discussion about cancer and the role of alcohol consumption, indicating no healthy dose of ethanol and challenges with the French Paradox 8.

    Each clip covers different aspects related to atherosclerosis prevention, including lifestyle choices, clinical markers, and pharmacological interventions.

  • RELATED QUESTIONS